276 related articles for article (PubMed ID: 17409288)
1. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications.
Dunning BE; Gerich JE
Endocr Rev; 2007 May; 28(3):253-83. PubMed ID: 17409288
[TBL] [Abstract][Full Text] [Related]
2. Glucagon antagonism as a potential therapeutic target in type 2 diabetes.
Bagger JI; Knop FK; Holst JJ; Vilsbøll T
Diabetes Obes Metab; 2011 Nov; 13(11):965-71. PubMed ID: 21615669
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
4. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia.
Gu W; Yan H; Winters KA; Komorowski R; Vonderfecht S; Atangan L; Sivits G; Hill D; Yang J; Bi V; Shen Y; Hu S; Boone T; Lindberg RA; Véniant MM
J Pharmacol Exp Ther; 2009 Dec; 331(3):871-81. PubMed ID: 19720878
[TBL] [Abstract][Full Text] [Related]
5. The role of dysregulated glucagon secretion in type 2 diabetes.
D'Alessio D
Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():126-32. PubMed ID: 21824266
[TBL] [Abstract][Full Text] [Related]
6. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
Henkel E; Menschikowski M; Koehler C; Leonhardt W; Hanefeld M
Metabolism; 2005 Sep; 54(9):1168-73. PubMed ID: 16125528
[TBL] [Abstract][Full Text] [Related]
7. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block.
Moon JS; Won KC
Diabetes Metab J; 2015 Feb; 39(1):1-9. PubMed ID: 25729706
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition.
Singh V; Grötzinger C; Nowak KW; Zacharias S; Göncz E; Pless G; Sauer IM; Eichhorn I; Pfeiffer-Guglielmi B; Hamprecht B; Wiedenmann B; Plöckinger U; Strowski MZ
Endocrinology; 2007 Aug; 148(8):3887-99. PubMed ID: 17525126
[TBL] [Abstract][Full Text] [Related]
10. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
11. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
Creutzfeldt W
Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
[TBL] [Abstract][Full Text] [Related]
12. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
13. [Glucagon antagonists open a new way in treatment of type 2 diabetes Mellitus].
Vondra K
Vnitr Lek; 2016; 62(7-8):661-6. PubMed ID: 27627094
[TBL] [Abstract][Full Text] [Related]
14. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
15. Importance of postprandial glucose control.
Bell DS
South Med J; 2001 Aug; 94(8):804-9. PubMed ID: 11549192
[TBL] [Abstract][Full Text] [Related]
16. Importance of postprandial glucose levels as a target for glycemic control in type 2 diabetes.
Tibaldi J
South Med J; 2009 Jan; 102(1):60-6. PubMed ID: 19077774
[TBL] [Abstract][Full Text] [Related]
17. Islet cell function: alpha and beta cells--partners towards normoglycaemia.
Göke B
Int J Clin Pract Suppl; 2008 Mar; (159):2-7. PubMed ID: 18269435
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy of hyperglycemia.
Kulasa KM; Henry RR
Expert Opin Pharmacother; 2009 Oct; 10(15):2415-32. PubMed ID: 19743938
[TBL] [Abstract][Full Text] [Related]
19. Beta-cell function and mass in type 2 diabetes.
Larsen MO
Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
